Share this article
Share this article
EAGAN, Minn., Jan. 12, 2021 /PRNewswire/ Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a research collaboration with AstraZeneca(LSE/STO/Nasdaq: AZN) in a first of its kind study to inform the knowledge base of Neurofibromatosis Type 1 (NF1).
NF1 is a pediatric disease that affects 1 in 3,000 births. NF1 patients suffer from a variety of manifestations including learning disabilities, scoliosis, and are predisposed to tumor development. In April 2020, selumetinib became the first FDA approved therapy for NF1 patients for the treatment of symptomatic, inoperable plexiform neurofibromas.
EAGAN, Minn., Jan. 12, 2021 /PRNewswire/ Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a research collaboration with AstraZeneca(LSE/STO/Nasdaq:
By John Underwood / john@gulfcoastmedia.com
ROBERTSDALE, Alabama Cadets from Robertsdale and Elberta high schools celebrated their achievements and talked about the challenges of the past year as part of the annual “Pass-In-Review” conducted Wednesday, Dec. 9 at Robertsdale High School.
Because of travel restrictions, the annual inspection, which would have been conducted by new NJROTC Area 8 Commander Michael Mullen, was instead conducted by Baldwin County Schools Superintendent Eddie Tyler.
“On behalf of the Board of Education, I want to say how proud I am of this group of students,” Tyler said, “who have set and are already achieving their goals. They are a testament to their communities and a prime example of what is being accomplished here in Central Baldwin County.”